The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
Open accessAbstract
Aptamers are a class of small nucleic acid ligands that are composed of RNA or single-stranded DNA oligonucleotides and have high specificity and affinity for their targets. Similar to antibodies, aptamers interact with their targets by recognizing a specific three-dimensional structure and are thus termed "chemical antibodies." In contrast to protein antibodies, aptamers offer unique chemical and biological characteristics based on their oligonucleotide properties. Hence, they are more suitable for the development of novel clinical applications. Aptamer technology has been widely investigated in various biomedical fields for biomarker discovery, in vitro diagnosis, in vivo imaging, and targeted therapy. This review will discuss the potential applications of aptamer technology as a new tool for targeted cancer therapy with emphasis on the development of aptamers that are able to specifically target cell surface biomarkers. Additionally, we will describe several approaches for the use of aptamers in targeted therapeutics, including aptamer-drug conjugation, aptamer-nanoparticle conjugation, aptamer-mediated targeted gene therapy, aptamer-mediated immunotherapy, and aptamer-mediated biotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase
Cerchia, L., Ducongé, F., Pestourie, C., Boulay, J., Aissouni, Y., Gombert, K., Tavitian, B., de Franciscis, V., & Libri, D. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030123 · Cited by 246
RetractedDifferential SELEX in Human Glioma Cell Lines
Cerchia, L., Esposito, C. L., Jacobs, A. H., Tavitian, B., & de Franciscis, V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007971 · Cited by 65
RetractedTuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Aptamers evolved from live cells as effective molecular probes for cancer study
Shangguan, D., Li, Y., Tang, Z., Cao, Z. C., Chen, H. W., Mallikaratchy, P., Sefah, K., Yang, C. J., & Tan, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602615103 · Cited by 1,516
Self-citationCell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Cited by
Contrast agents for molecular photoacoustic imaging
Weber, J., Beard, P. C., & Bohndiek, S. E. (2016) · Nature Methods · doi:10.1038/nmeth.3929 · Cited by 1,270
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
DNA Functional Materials Assembled from Branched DNA: Design, Synthesis, and Applications
Dong, Y., Yao, C., Zhu, Y., Yang, L., Luo, D., & Yang, D. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00294 · Cited by 533
The Medicinal Chemistry of Therapeutic Oligonucleotides
Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 429
Optochemical Control of Biological Processes in Cells and Animals
Ankenbruck, N., Courtney, T., Naro, Y., & Deiters, A. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201700171 · Cited by 419
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Polymeric Delivery of Therapeutic Nucleic Acids
Kumar, R., Santa Chalarca, C. F., Bockman, M. R., Bruggen, C. V., Grimme, C. J., Dalal, R. J., Hanson, M. G., Hexum, J. K., & Reineke, T. M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00997 · Cited by 365
Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery
Rohovie, M. J., Nagasawa, M., & Swartz, J. R. (2017) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10049 · Cited by 340
Inorganic nanoparticles: A potential cancer therapy for human welfare
Pugazhendhi, A., Edison, T. N. J. I., Karuppusamy, I., & Kathirvel, B. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.01.034 · Cited by 325
A Highlight of Recent Advances in Aptamer Technology and Its Application
Sun, H., & Zu, Y. (2015) · Molecules · doi:10.3390/molecules200711959 · Cited by 316
Self-citationUltrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications
Zarschler, K., Rocks, L., Licciardello, N., Boselli, L., Polo, E., Garcia, K. P., De Cola, L., Stephan, H., & Dawson, K. A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.02.019 · Cited by 303
Active targeting of gold nanoparticles as cancer therapeutics
Goddard, Z. R., Marín, M. J., Russell, D. A., & Searcey, M. (2020) · Chemical Society Reviews · doi:10.1039/d0cs01121e · Cited by 282
Gajbhiye, K. R., Salve, R., Narwade, M., Sheikh, A., Kesharwani, P., & Gajbhiye, V. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01849-0 · Cited by 262
Vimentin Intermediate Filaments as Potential Target for Cancer Treatment
Strouhalova, K., Přechová, M., Gandalovičová, A., Brábek, J., Gregor, M., & Rosel, D. (2020) · Cancers · doi:10.3390/cancers12010184 · Cited by 255
Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy
Jo, S. D., Ku, S. H., Won, Y.-Y., Kim, S. H., & Kwon, I. C. (2016) · Theranostics · doi:10.7150/thno.15335 · Cited by 218
Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
Mercier, M.-C., Dontenwill, M., & Choulier, L. (2017) · Cancers · doi:10.3390/cancers9060069 · Cited by 113
SIDT2 mediates gymnosis, the uptake of naked single-stranded oligonucleotides into living cells
Takahashi, M., Contu, V. R., Kabuta, C., Hase, K., Fujiwara, Y., Wada, K., & Kabuta, T. (2017) · RNA Biology · doi:10.1080/15476286.2017.1302641 · Cited by 47
Dong, H., Han, L., Wu, Z.-S., Zhang, T., Xie, J., Ma, J., Wang, J., Li, T., Gao, Y., Shao, J., et al. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.7b03044 · Cited by 36
Metadata
- Authors
- Sun, H., Zhu, X., Lu, P. Y., Rosato, R. R., Tan, W., & Zu, Y.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 3
- Pages
- e182
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2002089022
- Cited by
- 541
- References
- 129
- FWCI
- 20.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.